综述

重组人凝血因子Ⅶ的研究进展

  • 朱琳 楼觉人
展开
  • 200052 上海生物制品研究所有限责任公司第二研究室

网络出版日期: 2025-08-16

Research progress on recombinant human coagulation factor Ⅶ

Expand
  • No.2 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai 200052, China

Online published: 2025-08-16

摘要

 人凝血因子Ⅶ(human coagulation factor Ⅶ,hFⅦ)是参与血液凝血级联反应的蛋白之一,在凝血过程中发挥极其重要的作用。hFⅦ主要用于治疗和预防先天性或获得性血友病患者的出血,还可用于非血友病患者的创伤性大出血。通过基因工程技术制备hFⅦ不仅安全,而且还易于大规模生产。已有文献报道在利什曼原虫、昆虫细胞、多种哺乳动物细胞以及转基因兔乳腺中成功表达重组hFⅦ。因此,开发能高效表达重组hFⅦ的表达系统,将使大规模生产hFⅦ成为可能。

本文引用格式

朱琳 楼觉人 . 重组人凝血因子Ⅶ的研究进展[J]. 国际生物制品学杂志, 2015 , 38(1) : 31 -35 . DOI: 10.3760/cma.j.issn.1673-4211.2015.01.008

Abstract

 Human coagulation factor Ⅶ (hFⅦ) is one of the proteins involved in blood coagulation cascade, and plays an important role in the coagulation process. hFⅦis indicated for the prevention and treatment of bleeding episodes in congenital or acquired hemophilia patients. In addition, hFⅦ can also be used for treatment of bleeding in trauma patients. Recombinant hFⅦ (rhFⅦ) produced by genetic engineering techniques is not only safe, but also easy for mass production. It is reported that rhFⅦ has been successfully expressed in Leishmania, insect cells, a variety of mammalian cells and mammary gland of transgenic rabbits. Therefore, developing a expression system, which can express high-level hFⅦ, makes mass production of rhFⅦ possible.
文章导航

/